AR
HY
ZH-CN
EN
DE
EL
IT
FA
PT
ES
TR
JP
The phrase “prostate check” has long been associated with the digital rectal exam (DRE), but new screening approaches are combining PSA testing, advanced imaging, and risk-stratification tools to help physicians distinguish benign prostate enlargement (BPH) from potentially significant prostate cancer. As Men’s Health Month encourages men to take a proactive approach to their health, the 2026 American Urological Association (AUA) and Society of Urologic Oncology (SUO) guidelines have officially de-emphasized the DRE as a mandatory first-line screening tool for asymptomatic men.
While the approach to screening may be changing, the importance of early detection remains as critical as ever. Here’s what every Canadian man should know about modern prostate health screening this Men’s Health Month.
The 2026 American Urological Association (AUA) and Society of Urologic Oncology (SUO) guidelines do not eliminate prostate cancer screening. Instead, they refine the screening process by placing greater emphasis on evidence-based testing, individualized risk assessment, and shared decision-making between patients and healthcare providers. The updated approach also recognizes that elevated PSA levels can result from a variety of prostate conditions, including BPH, making careful evaluation more important than ever.
The updated guidelines recognize that for asymptomatic men considering prostate cancer screening, the prostate-specific antigen (PSA) blood test should remain the primary first-line screening tool. PSA testing provides an objective measurement that can help identify men who may benefit from additional evaluation.
Importantly, PSA levels can be influenced by factors other than prostate cancer. Common conditions such as BPH, which affects many aging men, can cause PSA levels to rise because a larger prostate naturally produces more PSA. For this reason, an elevated PSA result does not automatically indicate cancer and should be interpreted within the context of a patient’s overall prostate health.
Rather than recommending routine DRE for all men undergoing screening, the guidelines acknowledge that its role is more limited in the initial assessment of asymptomatic patients. This shift reflects growing evidence that routine DRE adds relatively little value as a broad screening tool when compared with PSA-based screening strategies.
Another important change is the continued focus on shared decision-making. Screening is no longer viewed as a one-size-fits-all process. Instead, healthcare providers are encouraged to consider factors such as:
This personalized approach helps ensure that screening decisions are tailored to each patient’s level of risk and healthcare goals.
PSA stands for prostate-specific antigen, a protein produced by both normal and abnormal prostate cells. Small amounts of PSA naturally enter the bloodstream, and a simple blood test can measure the level present in your blood. Because the prostate produces PSA, changes in PSA levels can sometimes signal that something is affecting the gland. This may include prostate cancer, but it can also be caused by several non-cancerous conditions, such as BPH.
One of the greatest challenges with prostate cancer is that it often develops silently. Many men with early-stage prostate cancer experience no symptoms at all. They may feel healthy, have no urinary concerns, and be unaware that cancer is present.
At the same time, many men experience urinary symptoms related to BPH, including frequent urination, urgency, a weak urinary stream, or waking up multiple times at night to urinate. Because both BPH and prostate cancer affect the prostate gland, healthcare providers use PSA testing as an important tool to help determine whether further evaluation may be necessary.
PSA testing helps identify men who may benefit from further evaluation before symptoms appear. Rather than waiting for warning signs, healthcare providers can use PSA results as an early indicator that additional testing or monitoring may be warranted. Additionally, according to a recent study by Cochrane Library, PSA screening was proven to reduce prostate cancer-specific mortality, with the possibility of reducing overall mortality.
The test itself is straightforward:
An elevated PSA level does not automatically indicate prostate cancer. In many cases, PSA elevations may be related to BPH, prostate inflammation, infection, or other benign causes. Because enlarged prostates often produce more PSA, men with BPH can have higher PSA levels even when cancer is not present. For this reason, a single PSA result is rarely viewed in isolation. Healthcare providers often look at trends over time, repeat testing when appropriate, and may recommend additional evaluations before drawing conclusions.
The updated prostate cancer screening guidelines are a powerful reminder that taking care of your prostate health isn’t about fear, it’s about taking control. Because early-stage prostate cancer often has no symptoms at all, waiting for signs to appear is no longer the strategy. Conversely, if you are experiencing changes in your urinary health—like a weak stream, frequent nighttime trips, or sudden urgency—remember that these are classic signs of BPH, not an automatic cancer diagnosis.
Because BPH and prostate cancer share similar warning signs and can both cause your PSA levels to fluctuate, getting an accurate evaluation is the only way to get true clarity.
The way we screen has evolved to become simpler, more precise, and less invasive. Don’t let outdated perceptions of prostate exams or old medical fears hold you back from protecting your long-term health. This Men’s Health Month, give yourself and your family the gift of certainty and book a consultation with BPH Canada today.
